US › Healthcare

UroGen Pharma Ltd (URGN)

US · Healthcare · Biotechnology

$39.92+3.45%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$51.0M
Revenue YoY
+151.6%
Net profit
$-23.6M
Profit YoY
+46.2%
EPS
$-0.47
EPS estimate
$-0.48
Net margin
-46.3%

EPS came in at -0.47 against a street estimate of -0.48 — a beat of 2.1%.

Key statistics

Market cap
$1.86B
Forward P/E
0.0
P/B
19.27
Book value
$-2.55
EPS (TTM)
$-2.74
52-week high
$43.93
52-week low
$15.86
50-day MA
$34.75
200-day MA
$25.09
Beta
1.57

Analyst view

Analysts rate UroGen Pharma Ltd a buy (6 buy, 2 hold, 0 sell out of 8) with an average price target of $44.75.

Shareholding

Insiders
3.62%
Institutions
101.74%

Largest institutional holders

FundStake
RTW INVESTMENTS, LLC9.33%
BlackRock Inc5.84%
The Toronto-Dominion Bank5.37%
Morgan Stanley - Brokerage Accounts5.25%
Kynam Capital Management, LP4.61%
Jefferies Financial Group Inc4.51%
Paradigm Biocapital Advisors LP3.50%
SG Americas Securities, LLC3.40%

Recent filings & reports

DocumentDate
Board / officer change · Q2 20262026-06-23
Company announcement · Q2 20262026-06-02
Quarterly report · Q1 20262026-05-06
Results announced · Q2 20262026-05-06
Proxy statement · Q4 20252026-04-30
Annual report FY20252026-03-02
Results announced · Q1 20262026-03-02
Quarterly report · Q3 20252025-11-06

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for UroGen Pharma Ltd — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.